Expert Interview
A Second Look: Discussing Allogene Therapeutics' Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Anti-CD19 CAR-T Therapy for First-Line Consolidation in Large B-Cell Lymphoma
Ticker(s): ALLO, BMY, GILD, PFE, RHHBY, MRKInstitution: South Nassau Oncology
- Senior Partner of South Nassau Oncology, Professor of Medicine at the Mount Sinai Hospital and Former Director of the Cancer Program at the Mount Sinai Hospital
- Manages 150 patients with large B-cell lymphoma, 25+ with NSCLC and 80 patients with AML
- Clinical focus on hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma and leukemias; as well as cancers of the lung, colon and breast.
How many patients do you manage with Large B-Cell Lymphoma?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Anti-CD19 CAR-T Therapy for First-Line Consolidation in Large B-Cell Lymphoma?
Added By: lilly_adminDoes this early positive data translate to long-term clinical durability, specifically EFS?
Added By: lilly_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
